DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2012; 137(40): 2023-2026DOI: 10.1055/s-0032-1305293 Nephrologie | Commentary Nephrologie © Georg Thieme Verlag KG Stuttgart · New YorkChronisches NierenversagenUpdate 2012Chronic kidney diseaseUpdate 2012 M. Ketteler 1 Medizinische Klink III, Nephrologische Abteilung, Klinikum Coburg , C. Wanner 2 Medizinische Klinik und Poliklinik 1, Schwerpunkt Nephrologie, Universitäts- klinikum Würzburg› Author AffiliationsRecommend Article Abstract Buy ArticleSchlüsselwörter Schlüsselwörterchronische Nierenkrankheit - Prinzipien der Progressionshemmung - Phosphatzusätze - FGF23 Keywords Keywordschronic kidney disease (CKD) - principles of inhibiting progression - phosphate additives - FGF23 Full Text References Literatur 1 Bellasi A, Mandreoli M, Baldrati L et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011; 6: 883-891 2 Bello AK, Hemmelgarn B, Lloyd A et al. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin J Am Soc Nephrol 2011; 6: 1418-1426 3 K/DOQI, National Kidney Foundation. Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2000; 35 (Suppl. 02) 1-140 4 Cupisti A, Benini O, Ferretti V et al. Novel differential measurement of natural and added phosphorus in cooked ham with or without preservatives. J Ren Nutr 2012; Mar 8. [Epub ahead of print] 5 de Boer IH, Katz R, Chonchol M et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol 2011; 6: 2141-2149 6 de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20: 2075-2084 7 Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408 8 Gansevoort RT, Matsushita K, van der Velde M et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. Kidney Int 2011; 80: 93-104 9 Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305 10 Gutiérrez OM, Anderson C, Isakova T et al. CRIC Study Group. Low socioeconomic status associates with higher serum phosphate irrespective of race. J Am Soc Nephrol 2010; 21: 1953-1960 11 Inker LA, Schmid CH, Tighiouart H et al. CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. New Engl J Med 2012; 367: 20-29 12 Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378 13 Isakova T, Xie H, Yang W. Chronic Renal Insufficiency Cohort (CRIC) Study Group et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439 14 Iseki K, Ikemiya Y, Iseki C et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474 15 Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease. Kidney Int 2011; 80: 17-28 16 Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril. Ann Intern Med 2001; 134: 629-636 17 Mann JF, Schmieder RE, McQueen M et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet 2008; 372: 547-553 18 McMurray JJ, Abraham WT, Dickstein K et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14: 341-343 19 Ritz E, Hahn K, Ketteler M et al. Phosphate additives in food – a health risk. Dtsch Arztebl Int 2012; 109: 49-55 20 Schmieder RE, Mann JF, Schumacher H et al. ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364 21 Shinaberger CS, Greenland S, Kopple JD et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. Am J Clin Nutr 2008; 88: 1511-1518 22 Susantitaphong P, Sewaralthahab K, Balk EM et al. Short- and long-term effects of alkali therapy in chronic kidney disease. Am J Nephrol 2012; 35: 540-547 23 van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. Kidney Int 2011; 79: 1341-1352 24 Wanner C, Ketteler M. Chronisches Nierenversagen. Dtsch Med Wochenschr 2011; 136: 1591-1593 25 Zoccali C, Ruggenenti P, Perna A et al. REIN Study Group. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930
